Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: Fierce 15 nominations are now open! We're looking for the best and brightest in biotech.
failed trials
Biotech
Merck halts phase 3 melanoma TIGIT trial due to discontinuations
Merck & Co. has bailed on a phase 3 test of anti-TIGIT drug vibostolimab after a high rate of discontinuations rendered the trial's success unlikely.
James Waldron
May 13, 2024 8:39am
GlycoMimetics fails phase 3 blood cancer trial, sinking stock
May 6, 2024 8:11am
Annovis shares plummet 60% after muddled Alzheimer’s readout
Apr 29, 2024 11:45am
Addex's Janssen-partnered epilepsy drug fails phase 2 trial
Apr 29, 2024 8:44am
Sage fails first of 4 tests for key prospect, exits Parkinson's
Apr 17, 2024 8:34am
Gritstone ground down by phase 2 cancer vaccine fail
Apr 2, 2024 5:09am